NCT01672762已完成3 期
Phase III Study of ASP1941 -A Phase III, Open-Label, Uncontrolled, Monotherapy Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 174
- 主要终点
- Change in HbA1c
研究概览
简要总结
This study is to evaluate safety and efficacy of ASP1941 after 24 week administration to diabetic patients.
详细描述
Subjects will undergo the 6-week screening period before entering the 24-week treatment period and will receive ASP1941 before breakfast during the treatment period. All subjects will be followed for 4 weeks after study treatment is discontinued.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type 2 diabetes mellitus patients
- •Subject is only on a diet and exercise program or has received a single antihyperglycemic agent or two antihyperglycemic agents (excluding insulin) with low dose (≤50% of the maximum dose of each recommended dosage)
- •Subject has a HbA1c value (JDS value) between 6.5% and 9.5% and the difference of HbA1c values (JDS value) within ± 1.0%
- •BMI 20.0 - 45.0 kg/m2
排除标准
- •Type 1 Diabetes Mellitus
- •Subject has received insulin within 12 weeks (84 days) before the study
- •Subject has proliferative diabetic retinopathy
- •Subject has a history of clinically significant renal disease such as renovascular occlusive disease, nephrectomy and/or renal transplant
- •Subject with obvious dysuria caused by a neurogenic bladder or a benign prostatic hypertrophy
- •Subject has a history of cerebral vascular attack, unstable angina, myocardial infarction, vascular intervention, and heart disease (NYHA Class III-IV) within 12 weeks (84 days). Subject has heart disease, cerebral vascular disease which, in the opinion of the principal investigator or the sub-investigator, may interfere with treatment or evaluation of safety of this study.
- •Female subject who is currently pregnant or lactating, or who is possibly pregnant
- •Male and pre-menopausal Female subject who cannot use an appropriate contraception during the study
- •Subject has a history of treatment with ASP1941
- •Subject has participated in another clinical study, post marketing study, or medical equipment study within 12 weeks (84 days) before providing written informed consent, or who is currently participating in any of those studies
- •Subject has a serum creatinine value higher than upper limit of normal range
- •Subject has a urinary microalbumin/ urinary creatinine ratio > 300 mg/g in urinalysis
- •Subject has uncontrolled severe hypertension (subject whose systolic blood pressure is > 170 mmHg or diastolic blood pressure of > 95 mmHg measured in a sitting position after 5 minutes of rest
- •Subject who is judged inappropriate for enrollment into the study by the principal investigator or the sub-investigator
研究组 & 干预措施
ASP1941 group
Experimental
oral
干预措施: ipragliflozin (Drug)
结局指标
主要结局
Change in HbA1c
时间窗: Before and at 4-, 8-, 12-, 16-, 20- and 24-week
次要结局
- Change in fasting serum insulin(Before and at 4-, 8-, 12-, 16-, 20- and 24-week)
- Change in waist circumference(Before and at 4-, 8-, 12-, 16-, 20- and 24-week)
- Change in body weight(Before and at 4-, 8-, 12-, 16-, 20- and 24-week)
- Safety assessed by the incidence of adverse events, vital signs, lab-tests and 12-lead ECGs(24 weeks)
- Change in fasting plasma glucose(Before and at 4-, 8-, 12-, 16-, 20- and 24-week)
- Change in urine glucose(Before and at 4-, 8-, 12-, 16-, 20- and 24-week)
研究者
相似试验
已完成
3 期
A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes MellitusType 1 Diabetes MellitusNCT02897219Astellas Pharma Inc175
终止
3 期
A Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes MellitusType II Diabetes MellitusNCT01514838Astellas Pharma Inc46
已完成
3 期
A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic PatientsType 2 Diabetes MellitusNCT01242202Astellas Pharma Inc113
已完成
3 期
A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic PatientsType 2 Diabetes MellitusNCT01316107Astellas Pharma Inc122
已完成
3 期
A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic PatientsType 2 Diabetes MellitusNCT01242228Astellas Pharma Inc106